Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT04200625·Not applicable·OBSERVATIONAL

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

DulaglutideOtherCompleted

Status

Completed

Phase

Not applicable

Enrollment

80

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Full detailed description

This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records. Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Interventions

Treatment arms and agents.

No intervention details reported.

Timeline

From registration to results.

  1. First posted

    Dec 16, 2019

  2. Study start

    Sep 24, 2019

  3. Primary completion

    Dec 9, 2019

  4. Study completion

    Dec 9, 2019

  5. Results posted

    Not reported

  6. Registry updated

    May 10, 2023

Outcomes

What the study measures.

Primary outcomes

Epicardial Fat thickness

Time frame · 12 weeks

Ultrasound measured Epicardial Fat thickness

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
90 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Type 2 diabetes, * BMI ≥27 kg/m2, * Age ≥ 18 years old Exclusion Criteria: * Type 1 diabetes * Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors * History of diabetic ketoacidosis * Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2 * Acute infective diseases, cancer or chemotherapy * Use of systemic corticosteroids within the 3 months prior this study * Known or suspected allergy to semaglutide or dulaglutide excipients or related products * Pregnancy, breastfeeding or the intention of becoming pregnant

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

University of Miami

Miami, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Dulaglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsDulaglutide trial dashboard →DatabaseDulaglutide database entry →ResearchDulaglutide research guide →